NCT03465709View on ClinicalTrials.gov

Pegcetacoplan (APL-2) in Neovascular AMD

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

April 5, 2019

Study Completion Date

April 5, 2019

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Pegcetacoplan

Study Drug

Trial Locations (4)

21740

Apellis Clinical Site, Hagerstown

44122

Apellis Clinical Site, Cleveland

77030

Apellis Clinical Site, Houston

90211

Apellis Clinical Site, Beverly Hills

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY